Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Smolen

Showing results (1071-1080 of 1,467) with videos related to

Pageof 147
Sort By:
Leukemia Research|July 15, 2010
The efficacy and safety of the low-thalidomide dose CTD (cyclophosphamide, thalidomide, dexamethasone) regimen in patients with multiple myeloma--a report by the Polish Myeloma Study GroupAnna Dmoszynska, Adam Walter-Croneck, Iwona Hus, et al.
RMD Open|May 11, 2025
Upadacitinib as monotherapy in patients with rheumatoid arthritis and prior inadequate response to methotrexate: results at 260 weeks from the SELECT-MONOTHERAPY randomised studyJosef S Smolen, Paul Emery, William Rigby, et al.
RMD Open|April 17, 2018
Conversion to seronegative status after abatacept treatment in patients with early and poor prognostic rheumatoid arthritis is associated with better radiographic outcomes and sustained remission: post hoc analysis of the AGREE studyDiahann T S L Jansen, Paul Emery, Josef S Smolen, et al.
American Journal of Public Health|August 10, 2013
Social, behavioral, and genetic linkages from adolescence into adulthoodKathleen Mullan Harris, Carolyn Tucker Halpern, Jon Hussey, et al.
Arthritis Care & Research|January 8, 2020
Treatment-to-Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease ManifestationsPhilip J Mease, Dafna D Gladman, Alexis Ogdie, et al.
Oncology and Therapy|April 4, 2023
Component Costs of CAR-T Therapy in Addition to Treatment Acquisition Costs in Patients with Multiple MyelomaSundar Jagannath, Nedra Joseph, Concetta Crivera, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|January 29, 2024
Leveraging the holistic benefits of biosimilars in Europe - part 2: how payers can safeguard the future of a healthy biosimilar market environmentJorge Mestre-Ferrandiz, Marcin Czech, Josef S Smolen, et al.
Arthritis and Rheumatism|January 5, 2002
Adenovirus-based overexpression of tissue inhibitor of metalloproteinases 1 reduces tissue damage in the joints of tumor necrosis factor alpha transgenic miceG Schett, S Hayer, M Tohidast-Akrad, et al.
Drug and Alcohol Dependence|May 22, 2003
A genome-wide search for quantitative trait loci influencing substance dependence vulnerability in adolescenceMichael C Stallings, Robin P Corley, John K Hewitt, et al.
Annals of the Rheumatic Diseases|August 8, 2013
Development of patient-centred standards of care for rheumatoid arthritis in Europe: the eumusc.net projectMichaela A Stoffer, Josef S Smolen, Anthony Woolf, et al.
Pageof 147

Showing results (1071-1080 of 1,467) with videos related to

Sort By:
Pageof 147
Leukemia Research|July 15, 2010
The efficacy and safety of the low-thalidomide dose CTD (cyclophosphamide, thalidomide, dexamethasone) regimen in patients with multiple myeloma--a report by the Polish Myeloma Study GroupAnna Dmoszynska, Adam Walter-Croneck, Iwona Hus, et al.
RMD Open|May 11, 2025
Upadacitinib as monotherapy in patients with rheumatoid arthritis and prior inadequate response to methotrexate: results at 260 weeks from the SELECT-MONOTHERAPY randomised studyJosef S Smolen, Paul Emery, William Rigby, et al.
RMD Open|April 17, 2018
Conversion to seronegative status after abatacept treatment in patients with early and poor prognostic rheumatoid arthritis is associated with better radiographic outcomes and sustained remission: post hoc analysis of the AGREE studyDiahann T S L Jansen, Paul Emery, Josef S Smolen, et al.
American Journal of Public Health|August 10, 2013
Social, behavioral, and genetic linkages from adolescence into adulthoodKathleen Mullan Harris, Carolyn Tucker Halpern, Jon Hussey, et al.
Arthritis Care & Research|January 8, 2020
Treatment-to-Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease ManifestationsPhilip J Mease, Dafna D Gladman, Alexis Ogdie, et al.
Oncology and Therapy|April 4, 2023
Component Costs of CAR-T Therapy in Addition to Treatment Acquisition Costs in Patients with Multiple MyelomaSundar Jagannath, Nedra Joseph, Concetta Crivera, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|January 29, 2024
Leveraging the holistic benefits of biosimilars in Europe - part 2: how payers can safeguard the future of a healthy biosimilar market environmentJorge Mestre-Ferrandiz, Marcin Czech, Josef S Smolen, et al.
Arthritis and Rheumatism|January 5, 2002
Adenovirus-based overexpression of tissue inhibitor of metalloproteinases 1 reduces tissue damage in the joints of tumor necrosis factor alpha transgenic miceG Schett, S Hayer, M Tohidast-Akrad, et al.
Drug and Alcohol Dependence|May 22, 2003
A genome-wide search for quantitative trait loci influencing substance dependence vulnerability in adolescenceMichael C Stallings, Robin P Corley, John K Hewitt, et al.
Annals of the Rheumatic Diseases|August 8, 2013
Development of patient-centred standards of care for rheumatoid arthritis in Europe: the eumusc.net projectMichaela A Stoffer, Josef S Smolen, Anthony Woolf, et al.
Pageof 147